Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study.

about

Simplified identification of disulfide, trisulfide, and thioether pairs with 213 nm UVPD

P2860

Q57800813-463C9993-F43E-4534-930B-A4392ED7E628

P2860

Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study.

Item

http://www.wikidata.org/entity/Q50098437

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Assessment of structural and f ...... ts: Rituximab as a case study.

@en

Assessment of structural and f ...... ts: Rituximab as a case study.

@nl

type

Item

label

Assessment of structural and f ...... ts: Rituximab as a case study.

@en

Assessment of structural and f ...... ts: Rituximab as a case study.

@nl

prefLabel

Assessment of structural and f ...... ts: Rituximab as a case study.

@en

Assessment of structural and f ...... ts: Rituximab as a case study.

@nl

P1476

Assessment of structural and f ...... ts: Rituximab as a case study.

@en

P2093

Anurag S Rathore

http://www.w3.org/2001/XMLSchema#string

Neh Nupur

http://www.w3.org/2001/XMLSchema#string

Nidhi Chhabra

http://www.w3.org/2001/XMLSchema#string

Rozaleen Dash

http://www.w3.org/2001/XMLSchema#string

P2860

Rituximab: mechanism of action

The N-end rule: functions, mysteries, uses

Fc glycans of therapeutic antibodies as critical quality attributes

Protein comparability assessments and potential applicability of high throughput biophysical methods and data visualization tools to compare physical stability profiles

Structural basis for recognition of CD20 by therapeutic antibody Rituximab

Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc RIII and antibodies lacking core fucose

Acceptable changes in quality attributes of glycosylated biopharmaceuticals

Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab

A platform for characterizing therapeutic monoclonal antibody breakdown products by 2D chromatography and top-down mass spectrometry.

Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques.

P304

143-158

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/19420862.2017.1402996

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29200314

http://www.w3.org/2001/XMLSchema#string

P932

5800382

http://www.w3.org/2001/XMLSchema#string

Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study.

about

P2860

P2860

Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932